PAUL LEMANSKI, M.D., F.A.C.P.
Public Health & General Preventive Medicine Physician in ALBANY, New York. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
PAUL LEMANSKI, M.D., F.A.C.P. reported a CMS MIPS final score of 86.4474/100 — above the 83.1 national average — and filed 4,482 Medicare Part D claims in 2023.
- 86.4474/100
- MIPS score · +3 vs avg
- 4K
- Part D claims, 2023
- 90%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
PAUL LEMANSKI, M.D., F.A.C.P.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
86 Top 48% higher than 52% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
PAUL LEMANSKI, M.D., F.A.C.P. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about PAUL LEMANSKI, M.D., F.A.C.P.?
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in New York
How Public Health & General Preventive Medicine Physician compares to other specialties among New York providers
Public Health & General Preventive Medicine Physician share within New York
Public Health & General Preventive Medicine Physician is one of the more visible NUCC categories in New York
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
PAUL LEMANSKI, M.D., F.A.C.P.'s 2023 MIPS final score plotted against the Public Health & General Preventive Medicine Physician national average
- MIPS Final Score
- 86.4474/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Public Health & General Preventive Medicine Physician) — 86.4474/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Public Health & General Preventive Medicine Physician US NPIs
86.4474/100 MIPS final score — 3.3 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Public Health & General Preventive Medicine Physician. Quality dim: 98.0507. Cost dim: 56.774.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
PAUL LEMANSKI, M.D., F.A.C.P. appears in the CMS NPPES registry as a Public Health & General Preventive Medicine Physician provider holding M.D., F.A.C.P. credentials at 4 PALISADES DR STE 130, ALBANY, NY, 12205, with a listed phone of (518) 722-0099. NPI 1831190016 was issued on 08/10/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what LEMANSKI most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 4,482 prescription claims written by this provider, covering 326 Medicare beneficiaries and totaling roughly $477K in drug spend, split 10% brand-name and 90% generic by claim count, with an opioid prescribing rate of 2.3%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 86.4474/100 for the 2023 performance year (Quality 98.0507, Cost 56.774), compared with the national average of 83.1.
Public Health & General Preventive Medicine Physician is a narrow specialty nationwide, with 1,764 enrolled providers across 52 states and an average of 968 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1831190016 |
|---|---|
| Specialty | Public Health & General Preventive Medicine Physician |
| Credentials | M.D., F.A.C.P. |
| Gender | Male |
| NPI Issued | 08/10/2005 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm PAUL LEMANSKI, M.D., F.A.C.P.'s current license status, disciplinary history, and board certifications with the New York State Education Department, Office of the Professions in New York before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Individual
Hospital and facility affiliations
Facilities where PAUL LEMANSKI, M.D., F.A.C.P. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for PAUL LEMANSKI, M.D., F.A.C.P.. Source: openpaymentsdata.cms.gov.
Total received
$570
Largest payer
Novartis Pharmaceuticals Corporation
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context — New York NYSBPMC 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 — they are NOT specific to PAUL LEMANSKI, M.D., F.A.C.P.. To verify PAUL LEMANSKI, M.D., F.A.C.P.'s current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
10% brand-name claims vs 90% generic, on 4,482 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 11,223
- Total Day Supply
- 329,079
- Brand vs Generic
- 10% brand / 90% generic
- Brand Drug Cost
- $364K
- Generic Drug Cost
- $111K
- Opioid Claims
- 105 (2.3% rate)
- Antibiotic Claims
- 135
Patient Demographics
- Average Patient Age
- 75.5 years
- Avg HCC Risk Score
- 1.14
- Gender Split
- 34% female / 66% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What PAUL LEMANSKI, M.D., F.A.C.P. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Ezetimibe
Ezetimibe
417 claims
- Atorvastatin Calcium
Atorvastatin Calcium
262 claims
- Amlodipine Besylate
Amlodipine Besylate
225 claims
- Rosuvastatin Calcium
Rosuvastatin Calcium
207 claims
- Omeprazole
Omeprazole
189 claims
- Losartan Potassium
Losartan Potassium
188 claims
- Levothyroxine Sodium
Levothyroxine Sodium
168 claims
- Pravastatin Sodium 122
Pravastatin Sodium
122 claims
| Drug | Claims |
|---|---|
| Ezetimibe | 417 |
| Atorvastatin Calcium | 262 |
| Amlodipine Besylate | 225 |
| Rosuvastatin Calcium | 207 |
| Omeprazole | 189 |
| Losartan Potassium | 188 |
| Levothyroxine Sodium | 168 |
| Pravastatin Sodium | 122 |
| Metformin Hcl | 106 |
| Simvastatin | 103 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Public Health & General Preventive Medicine Physician Overview
How PAUL LEMANSKI, M.D., F.A.C.P. fits within the Public Health & General Preventive Medicine Physician landscape nationally.
PAUL LEMANSKI, M.D., F.A.C.P.'s 4,482 claims are above the specialty average of 968.
Nearby Public Health & General Preventive Medicine Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as LEMANSKI.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore New York
Frequently Asked Questions
What is PAUL LEMANSKI, M.D., F.A.C.P.'s specialty? ▼
How much does PAUL LEMANSKI, M.D., F.A.C.P. prescribe under Medicare Part D? ▼
What is PAUL LEMANSKI, M.D., F.A.C.P.'s Medicare quality score? ▼
Where is PAUL LEMANSKI, M.D., F.A.C.P. located? ▼
What is PAUL LEMANSKI, M.D., F.A.C.P.'s NPI number? ▼
Does PAUL LEMANSKI, M.D., F.A.C.P. prescribe more brand-name or generic drugs? ▼
Does PAUL LEMANSKI, M.D., F.A.C.P. prescribe opioids? ▼
How many Public Health & General Preventive Medicine Physician providers are there in the US? ▼
What drugs does PAUL LEMANSKI, M.D., F.A.C.P. prescribe most often? ▼
Does PAUL LEMANSKI, M.D., F.A.C.P. accept Medicare? ▼
How can I verify PAUL LEMANSKI, M.D., F.A.C.P.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology